Abstract: bjective To investigate the efficacy of body gamma knife sequential gemcitabine plus lobaplatin regimen on unresectable pancreatic cancer. Methods Retrospective analysis of body gamma knife sequential gemcitabine plus lobaplatin regimen was made on 30 cases of unresectable pancreatic cancer. The isodose curve of body gamma knife was 40％-60％ and covered about 95％ of the target volume. For tumor more than 3cm in diameter，the single dose was 3.3-5Gy，once per day，and 5 times for a week with a total of 9 to 11 times. For the tumor less than 3cm in diameter，the single dose was 3.5-4Gy，once per day，and 5 times a week with a total of 8 to 9 times. The total dose was 31.5-45Gy. Gemcitabine 1000mg／m2 iv d1，d8；lobaplatin 30-40mg／m2 iv，d1. Twenty-one days was a cycle. 4 cycles was performed after the body gamma knife therapy. Results Twenty-four completed radiotherapy and chemotherapy in the 30 patients, with 3 cases in CR, 16 cases in PR, 6 case in SD, 5 cases in PD, and the response rate was 63.3%. The clinic benefit rate was 80.0%. The median overall survival was 11.6 months and the 1-，2-year survival rates were 39.0％ and 9.6％. The major adverse reactions were the digestive system reaction and haematological toxicity. The main manifestations were nausea and vomiting，leucopenia and thrombocytopenia with grade 1-3. No grade 4 adverse reaction was observed. Conclusion For patients with unresectable pancreatic carcinoma，body gamma knife sequential gemcitabine plus lobaplatin regimen can bring a survival benefit with tolerable adverse reaction，and worth further study.